Literature DB >> 22958186

Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.

Sílvia Saumell1, Lourdes Florensa, Elisa Luño, Carmen Sanzo, Consuelo Cañizo, Jesus M Hernández, José Cervera, Miguel A Gallart, Félix Carbonell, Rosa Collado, Leonor Arenillas, Carme Pedro, Joan Bargay, Benet Nomdedeu, Blanca Xicoy, Teresa Vallespí, José M Raya, Luis Belloch, Guillermo F Sanz, Francesc Solé.   

Abstract

Trisomy 8 is the most common chromosomal gain in myelodysplastic syndromes (MDS), however, little is known about the features of MDS with isolated trisomy 8 and the influence of additional cytogenetic aberrations. We determined the characteristics and prognostic factors of 72 patients with trisomy 8 as a single anomaly and analysed also the impact of other aberrations added to trisomy 8 in another 62 patients. According to our study, MDS with isolated trisomy 8 was more frequent in men, with more than one cytopenia in most patients (62%) and having about 4% bone marrow blasts. The multivariate analysis demonstrated that platelet count and percentage bone marrow blasts had the strongest impact on overall survival (OS). The median OS for isolated trisomy 8, trisomy 8 plus one aberration (tr8 + 1), plus two (tr8 + 2) and plus three or more aberrations (tr8 + ≥3) was 34·3, 40, 23·4 and 5·8 months, respectively (P < 0·001). Trisomy 8 confers a poorer prognosis than a normal karyotype in MDS patients with ≥5% bone marrow blasts. This study supports the view that MDS with isolated trisomy 8 should be included in the intermediate cytogenetic risk group.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22958186     DOI: 10.1111/bjh.12035

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Standardizing the initial evaluation for myelodysplastic syndromes.

Authors:  Danielle Marshall; Gail J Roboz
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?

Authors:  Sílvia Saumell; Francesc Solé; Leonor Arenillas; Julia Montoro; David Valcárcel; Carme Pedro; Carmen Sanzo; Elisa Luño; Teresa Giménez; Montserrat Arnan; Helena Pomares; Raquel De Paz; Beatriz Arrizabalaga; Andrés Jerez; Ana B Martínez; Judith Sánchez-Castro; Juan D Rodríguez-Gambarte; José M Raya; Eduardo Ríos; María Rodríguez-Rivera; Blanca Espinet; Lourdes Florensa
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 3.  The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications.

Authors:  Hassan Awada; Bicky Thapa; Valeria Visconte
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

Review 4.  Severe Inflammatory Response in Myelodysplastic Syndrome and Trisomy 8 Following 23-Valent Polysaccharide Pneumococcal Vaccine Administration.

Authors:  Hirohisa Fujikawa; Yusuke Miyazato; Kenichiro Ebisuda; Minoru Saito
Journal:  Turk J Haematol       Date:  2021-02-25       Impact factor: 1.831

Review 5.  Myelodysplastic Syndrome: Diagnosis and Screening.

Authors:  Francisco P Tria; Daphne C Ang; Guang Fan
Journal:  Diagnostics (Basel)       Date:  2022-06-29

6.  Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.

Authors:  Qing Fang Yue; Lei Chen; Xiao Mei She; Bin Hu; Yu Hu; Ping Zou; Xin Yue Liu
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.